Acute respiratory infections are one of the leading causes of morbidity and mortality worldwide. Accurate and timely diagnosis of viral infections can ensure appropriate treatment plans, reduce the cost of care and assist with controlling the spread of disease.
Adenovirus (AdV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RhV) are common respiratory pathogens responsible for cold-like illnesses amongst all age groups. However particularly in the young, eldely and immunocompromised, these viruses can progress to severe clinical manifestations, such as pneumonia, bronchitis, bronchiolitis and chronic obstructive pulmonary disease (COPD).123
Differential diagnosis of respiratory viral infections is therefore important for subsequent evaluation of antiviral drugs, prevention of secondary bacterial infections, or containment of potential outbreaks.
The cobas® ADV/hMPV/EV-RV UC Test assay for use with the cobas omni Utility Channel on the cobas® 6800/8800 Systems is a high-throughput multiplex assay for the qualitative detection and differentiation of respiratory viruses AdV, hMPV and EV/RhV.
Run fully compliant, CE-IVD workflow without further optimization. Positive and negative controls included.
Benefit from fully automated cobas® 6800/8800 Systems and an industry-leading menu to tackle seasonal high demand.
Create time and cost savings by testing up to three respiratory assays from a single sample without batching nor pre-sorting.
Test what is medically relevant and necessary by customizing a targeted menu to address patient needs according to test setting, seasonality and geography.
PPA = Positive Percent Agreement; NPA = Negative Percent Agreement; CI = confidence interval; LCL = Lower confidence Limit; UCL = Upper confidence Limit
PPA = Positive Percent Agreement; NPA = Negative Percent Agreement; CI = confidence interval; LCL = Lower confidence Limit; UCL = Upper confidence Limit
| Target | Number of Samples (N) | Concordant Positive (N) | Discordant Positive (N) | Concordant Negative (N) | Discordant Negative (N) | Agreement Parameter | Percent Agreement (%) | 95% CI (LCL,UCL) |
| ADV | 186 | 22 | 4* | 159 | 1 | PPA | 95.7% | (79.0%, 99.2%) |
| NPA | 97.5% | (93.9%, 99.0%) | ||||||
| MPV | 188 | 22 | 2* | 164 | 0 | PPA | 100% | (85.1%, 100.0%) |
| NPA | 98.6% | (95.7%, 99.7%) | ||||||
| EV/RV | 188 | 40 | 7* | 139 | 2** | PPA | 95.2% | (84.2%, 98.7%) |
| NPA | 95.2% | (90.4%, 97.7%) |
References
1. Centers for Disease Control and Prevention. About Adenoviruses. https://www.cdc.gov/adenovirus/about/index.html. Accessed 15 Jun 2021.
2. Hamelin ME, A bed Y, Boivin G. Human metapneumovirus: a new player among respiratory viruses. Clin Infect Dis. 2004;38(7):983-990. doi:10.1086/382536
3. Royston L, Tapparel C. Rhinoviruses and Respiratory Enteroviruses: Not as Simple as ABC. Viruses. 2016;8(1):16. Published 2016 Jan 11. doi:10.3390/v8010016
